VIVUS (NASDAQ:VVUS) announced its quarterly earnings data on Tuesday. The biopharmaceutical company reported ($0.10) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.13) by $0.03, Yahoo Finance reports. VIVUS had a return on equity of 344.23% and a net margin of 26.71%.
Shares of VIVUS (VVUS) traded down $0.03 during trading hours on Wednesday, reaching $0.50. The company’s stock had a trading volume of 690,921 shares, compared to its average volume of 645,822. The stock has a market capitalization of $52.70, a PE ratio of -1.71 and a beta of 0.57. VIVUS has a 1-year low of $0.38 and a 1-year high of $1.38. The company has a quick ratio of 7.09, a current ratio of 7.47 and a debt-to-equity ratio of 643.86.
A hedge fund recently raised its stake in VIVUS stock. Northern Trust Corp increased its position in VIVUS, Inc. (NASDAQ:VVUS) by 16.8% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 275,097 shares of the biopharmaceutical company’s stock after acquiring an additional 39,473 shares during the period. Northern Trust Corp owned about 0.26% of VIVUS worth $335,000 at the end of the most recent reporting period. Institutional investors own 24.92% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “VIVUS (VVUS) Issues Earnings Results” was first posted by American Banking News and is the sole property of of American Banking News. If you are reading this story on another site, it was illegally stolen and reposted in violation of U.S. & international trademark and copyright laws. The legal version of this story can be read at https://www.americanbankingnews.com/2018/03/14/vivus-vvus-issues-earnings-results.html.
VIVUS Company Profile
VIVUS, Inc is a biopharmaceutical company. The Company operates in the development and commercialization of therapeutic products segment. It provides over two therapies approved by the Food and Drug Association (FDA), which include Qsymia (phentermine and topiramate extended-release) for chronic weight management and STENDRA (avanafil) for erectile dysfunction (ED).
Receive News & Ratings for VIVUS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VIVUS and related companies with MarketBeat.com's FREE daily email newsletter.